Nunnelee Jordan, Cottini Francesca, Zhao Qiuhong, Faisal Muhammad Salman, Elder Patrick, Rosko Ashley, Bumma Naresh, Khan Abdullah, Devarakonda Srinivas, Benson Don M, Efebera Yvonne, Sharma Nidhi
College of Medicine, The Ohio State University, Columbus, OH 43210, USA.
Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.
Cancers (Basel). 2022 May 3;14(9):2277. doi: 10.3390/cancers14092277.
Multiple myeloma (MM) represents 1.8% of all new cancer cases in the U.S. While not curable, advances in treatment, including autologous stem cell transplant (ASCT) and maintenance therapy, have dramatically improved progression-free survival (PFS) and overall survival (OS). We performed a retrospective survival analysis on newly diagnosed MM (NDMM) patients receiving ASCT from 1992−2016 at the Ohio State University. A total of 1001 consecutive NDMM patients were eligible. Patients were split into five groups based on historic changes in novel agents for the treatment of MM. Across the years (1992−2016), there was a statistically significant improvement in both PFS (p < 0.01) and OS (p < 0.01). Significant improvements in both PFS and OS were seen in patients ≤65 years (p < 0.001 and p = 0.002) and >65 years old (p < 0.001 and p = 0.001), respectively. Improved PFS and OS were seen in both standard-risk (p < 0.001 and p < 0.001) and high-risk patients (p < 0.001 and p = 0.019). The post-transplant response showed statistically significant improvement across the years (p < 0.01). Survival rates for NDMM patients have significantly improved primarily due to the inclusion of novel therapies and post-ASCT maintenance.
多发性骨髓瘤（MM）占美国所有新发癌症病例的1.8%。虽然无法治愈，但包括自体干细胞移植（ASCT）和维持治疗在内的治疗进展显著改善了无进展生存期（PFS）和总生存期（OS）。我们对1992年至2016年在俄亥俄州立大学接受ASCT的新诊断MM（NDMM）患者进行了回顾性生存分析。共有1001例连续的NDMM患者符合条件。根据治疗MM的新型药物的历史变化，患者被分为五组。在这些年（1992 - 2016年）中，PFS（p < 0.01）和OS（p < 0.01）均有统计学显著改善。≤65岁（p < 0.001和p = 0.002）和>65岁（p < 0.001和p = 0.001）的患者在PFS和OS方面分别有显著改善。标准风险（p < 0.001和p < 0.001）和高风险患者（p < 0.001和p = 0.019）的PFS和OS均有所改善。移植后反应在这些年中有统计学显著改善（p < 0.01）。NDMM患者的生存率显著提高主要归因于新型疗法的纳入和ASCT后的维持治疗。
